A-LiNK: Improving Outcomes in Autoimmune Liver Disease

This study, called A-LiNK, is an observational study for children with autoimmune liver diseases like autoimmune hepatitis (AIH) and primary sclerosing cholangitis (PSC). It aims to create a shared network to collect information about these conditions, which can be challenging to diagnose and treat. Researchers will gather data on how the diseases progress, how often they relapse, and any complications that arise. The goal is to improve care by understanding current treatments and outcomes. You could be eligible if you have a clinical diagnosis of autoimmune hepatitis, primary sclerosing cholangitis, or autoimmune sclerosing cholangitis, and have not had a liver transplant.

Study design
This is an observational study, meaning no new treatments are being tested. It plans to include 800 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants' disease characteristics, relapse rates, and complications will be measured until 2034.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05750498

A-LiNK: Improving Outcomes in Autoimmune Liver Disease

Recruiting
Not specifiedAll AgesObservational
Children's Hospital Medical Center, Cincinnati
~800 participants
Updated 2026-08-19 on ClinicalTrials.gov
What's tested:No interventions

At a glance

Recruiting sites
8 of 8 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Baseline disease characteristics in the population
Measured over 2034
+5 more outcomes measured
Autoimmune Hepatitis
Primary Sclerosing Cholangitis
8 sites across 7 states
Ohio2
California1
Indiana1
Missouri1
Pennsylvania1
Texas1
Washington1
  • Amy E Taylor, MD · PRINCIPAL_INVESTIGATOR · Children's Hospital Medical Center, Cincinnati

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Clinical diagnosis of autoimmune hepatitis (AIH)
Clinical diagnosis of primary sclerosing cholangitis (PSC)
Clinical diagnosis of autoimmune sclerosing cholangitis (ASC)
  • Baseline disease characteristics in the population2034
  • Disease relapse and biochemical remission rates2034

    Biochemical remission = transaminases (ALT/AST) within the upper limit of normal for age

  • Complications of disease2034

    Including ascites, esophageal variceal bleeding, cholangitis, hepatic encephalopathy, listed for liver transplant, hepatocellular carcinoma, or cholangiocarcinoma

  • Side-effects of steroids2034

    Including hypertension, diabetes mellitus, low bone mineral density, glaucoma, cataract, overweight, obesity

  • Pediatric Quality of Life Inventory (PedsQL 4.0) Generic Core Scales Short Form 152034

    Health-related quality of life

  • Racial and ethnic disparities2034